Login / Signup

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis.

Guang LiYan-Hua ZhengLi XuJuan FengHai-Long TangCheng LuoYan-Ping SongXie-Qun Chen
Published in: Therapeutic advances in hematology (2020)
Combination of bortezomib with nitroxoline has a synergistic anti-tumor activity in MM cells and may be a novel treatment method for MM.
Keyphrases
  • multiple myeloma
  • induced apoptosis
  • cell cycle arrest
  • oxidative stress
  • newly diagnosed
  • cell death
  • cancer therapy